INVESTORS IR Nav Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Press Releases Press Releases Year None20212020 March 11, 2021 Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview March 10, 2021 Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference February 4, 2021 Protara Therapeutics to Present at Upcoming Virtual Investor Conferences February 2, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 2, 2021 Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors December 7, 2020 Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer December 3, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 24, 2020 Protara Therapeutics to Present at Upcoming Virtual Investor Conferences November 12, 2020 Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview November 11, 2020 Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference November 4, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 22, 2020 Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Next page › Last page » Displaying 13 - 24 of 39 IR Tools Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page IR Contact Justine O’Malley Vice President, Investor Relations and Communications Phone: 646-817-2836 Email: Justine.OMalley@protaratx.com
Press Releases Year None20212020 March 11, 2021 Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview March 10, 2021 Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference February 4, 2021 Protara Therapeutics to Present at Upcoming Virtual Investor Conferences February 2, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 2, 2021 Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors December 7, 2020 Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer December 3, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 24, 2020 Protara Therapeutics to Present at Upcoming Virtual Investor Conferences November 12, 2020 Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview November 11, 2020 Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference November 4, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 22, 2020 Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Next page › Last page » Displaying 13 - 24 of 39
March 11, 2021 Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview
March 10, 2021 Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference
February 2, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 7, 2020 Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer
December 3, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 12, 2020 Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview
November 11, 2020 Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
November 4, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 22, 2020 Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
